Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

Authors

Tim Kong, Washington University School of Medicine in St. Louis
Angelo B A Laranjeira, Washington University School of Medicine in St. Louis
Taylor B Collins, Washington University School of Medicine in St. Louis
Elisa S De Togni, Washington University School of Medicine in St. Louis
Abigail J Wong, Washington University School of Medicine in St. Louis
Mary C Fulbright, Washington University School of Medicine in St. Louis
Marianna Ruzinova, Washington University School of Medicine in St. Louis
Hamza Celik, Washington University School of Medicine in St. Louis
Grant A Challen, Washington University School of Medicine in St. Louis
Daniel A C Fisher, Washington University School of Medicine in St. Louis
Stephen T Oh, Washington University School of Medicine in St. Louis

Journal

Blood Advances

Publication Date

1-25-2022

Volume

6

Issue

2

First Page

611

Last Page

623

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2020002804

Rights and Permissions

Kong T, Laranjeira ABA, Collins TB, De Togni ES, Wong AJ, Fulbright MC, Ruzinova M, Celik H, Challen GA, Fisher DAC, Oh ST. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition. Blood Adv. 2022 Jan 25;6(2):611-623. doi: 10.1182/bloodadvances.2020002804. https://ashpublications.org/bloodadvances/article/6/2/611/477275/Pevonedistat-targets-malignant-cells-in © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Kong, Tim; Laranjeira, Angelo B A; Collins, Taylor B; De Togni, Elisa S; Wong, Abigail J; Fulbright, Mary C; Ruzinova, Marianna; Celik, Hamza; Challen, Grant A; Fisher, Daniel A C; and Oh, Stephen T, "Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition." Blood Advances. 6, 2. 611 - 623. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11374